News Results
There are 606,524 News Results
Nov 12, 2020
-- PDUFA Target Action Date of June 5, 2021 for Ryplazim(®) (plasminogen) BLA Submission -- Ryplazim(®) (plasminogen) Abstracts Selected for Presentation at American Society of Hematology (ASH) in early December...
Nov 12, 2020
NEW YORK and LONDON and IRVINE, Calif. and BASEL, Switzerland, Nov. 12, 2020 /PRNewswire/ -- Sumitovant Biopharma and Urovant Sciences (Nasdaq: UROV) today announced that they have entered into a...
Nov 12, 2020
LOUISVILLE, Ky., Nov. 12, 2020 /PRNewswire/ -- Creative Realities, Inc. ("Creative Realities," "CRI," or the "Company") (NASDAQ: CREX, CREXW), a leading provider of digital marketing solutions, announced its financial results...
Nov 12, 2020
SHANGHAI, Nov. 12, 2020 /PRNewswire/ -- In less than five years after its establishment, NextVPU has reinforced its leading position in the computer vision industry. Its "blockbuster products" are N1...
Nov 13, 2020
MONTREAL and CHARLOTTE, N.C., Nov. 13, 2020 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial...
Nov 13, 2020
BRIDGEWATER, N.J., Nov. 13, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today...
Nov 13, 2020
RARITAN, N.J., Nov. 13, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new 12-month data from the ongoing Phase 1/2 trial ( NCT03252847 ) of...
Nov 13, 2020
HOUSTON, Nov. 13, 2020 /PRNewswire/ -- The Company's third quarter results were driven by the economic effects of the COVID-19 pandemic, which affected the refining industry as a whole, and...
Nov 16, 2020
PALO ALTO, Calif., Nov. 16, 2020 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases,...
